Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05502250
Title Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | BEL


No variant requirements are available.